SAN DIEGO, March 1, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced that data from a Phase 4 clinical study of SUMAVEL ® DosePro™ (sumatriptan injection) Needle-free Delivery System will be presented in two posters at the 63 rd Annual Meeting of the American Academy of Neurology (AAN), to be held April 9 – 16, 2011 at the Hawaii Convention Center, Honolulu, HI. A summary of the Company's AAN presentations is below, and the abstracts can be accessed at the AAN website at www.aan.com. The Phase 4 open-label, multicenter U.S. study evaluated overall satisfaction, confidence and preference for SUMAVEL DosePro in treating multiple migraine attacks in more than 200 adult patients diagnosed with migraine and currently taking triptan therapy. Efficacy, including onset and sustained duration of pain relief/freedom from pain, and tolerability of therapy with SUMAVEL DosePro were also measured.
|Title:||Improved Treatment Satisfaction and Confidence Among Current Triptan Users Trying SUMAVEL® DosePro™ (needle-free subcutaneous sumatriptan) for Up to 4 Migraine Attacks|
|Authors:||Cady R, Aurora SK, Brandes JL, Rothrock J, Myers JA, Fox AW, Farr SJ|
|Date & Time:||Wednesday, April 13, 2011; 2:00PM – 6:00PM|
|Poster Number:||NO P05.275|
|Title:||Multiple-Attack Efficacy and Tolerability of SUMAVEL® DosePro™ (needle-free subcutaneous sumatriptan) Among Current Triptan Users|
|Authors:||Brandes JL, Rothrock J, Cady R, Aurora SK, Myers JA, Fox AW, Farr SJ|
|Date & Time:||Wednesday, April 13, 2011; 2:00PM – 6:00PM|
|Poster Number:||NO P05.283|
About SUMAVEL DoseProSUMAVEL DosePro (sumatriptan injection) is indicated for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache episodes. SUMAVEL DosePro should only be used where a clear diagnosis of migraine or cluster headache has been established. SUMAVEL DosePro is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine and should not be administered intravenously. For a given attack, if a patient does not respond to the first dose of SUMAVEL DosePro, the diagnosis of migraine or cluster headache should be reconsidered before administration of a second dose. IMPORTANT SAFETY INFORMATION SUMAVEL DosePro is contraindicated in patients with uncontrolled hypertension, in patients with history, symptoms or signs of ischemic heart disease, coronary artery vasospasm, cerebrovascular or peripheral vascular disease including ischemic bowel disease and in patients with other significant underlying cardiovascular diseases or known hypersensitivity to sumatriptan. SUMAVEL DosePro should not be given to patients in whom unrecognized coronary artery disease is predicted by the presence of risk factors without a prior cardiovascular evaluation. Serious cardiovascular events, including death, have been reported when taking sumatriptan, including patients with no findings of cardiovascular disease. Considering the extent of use of sumatriptan in patients with migraine, the incidence of these events is extremely low. Cerebrovascular events, some fatal, have been reported in patients treated with sumatriptan. In a number of cases, it appears possible that the cerebrovascular events were primary, sumatriptan having been administered in the incorrect belief the symptoms experienced were a consequence of migraine when they were not. It is important to advise patients not to administer SUMAVEL DosePro if a headache being experienced is atypical. SUMAVEL DosePro should not be used within 24 hours of other ergotamine-containing or ergot-type medications or other 5-HT1 agonists and is not generally recommended for use with MAO-A inhibitors. The development of a potentially life-threatening serotonin syndrome may occur with triptans, including treatment with SUMAVEL DosePro, particularly during combined use with selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). SUMAVEL DosePro should be used during pregnancy only if the potential benefit justifies the potential risk.
In controlled clinical trials with sumatriptan injection, the most common adverse reactions were injection site reactions, tingling, warm/hot sensation, burning sensation, feeling of heaviness, pressure sensation, feeling of tightness, numbness, feeling strange, tight feeling in head, flushing, tightness in chest, discomfort in nasal cavity/sinuses, jaw discomfort, dizziness/vertigo, drowsiness/sedation and headache.For full prescribing information, go to http://www.zogenix.com/docs/SV0018.0709A_SDP_PI.pdf For more information about SUMAVEL DosePro, please visit www.SUMAVELDosePro.com. About DosePro Technology The DosePro technology is an easy-to-use, pre-filled drug delivery system designed to enable self-administration of single doses of liquid drug formulations, subcutaneously, without a needle. The DosePro technology has undergone more than 10 years of design, process engineering, clinical evaluation and development work. DosePro is protected by more than 80 patents, issued and applied for, worldwide. Approximately 9,000 injections have been delivered in clinical trials in healthy volunteers using the DosePro needle-free drug delivery system. About Zogenix Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL(R) DosePro(TM) (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, ZX002, is a novel, oral, single-entity controlled-release formulation of hydrocodone currently in Phase 3 clinical trials for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. For additional information, please visit www.zogenix.com. Zogenix(TM) and DosePro(TM) are trademarks of Zogenix, Inc. SUMAVEL(R) is a registered trademark of Zogenix, Inc.
CONTACT: INVESTORS: Sara Pellegrino | The Ruth Group 646.536.7002 | firstname.lastname@example.org MEDIA: Jason Rando | The Ruth Group 646.536.7025 | email@example.com